Request an invite

Papzimeos: how long were the pivotal tox studies?

zopapogene imadenovec · HPV6/11 antigens (gorilla adenovirus)
Longest pivotal study
3 weeks
“Dosing Regimen Once weekly for three weeks, a total of three administrations on Days 0,7, and 14 for all groups.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
Pivotal GLP studies
Single non-GLP repeat-dose SC mouse study (1x10^10 VP weekly x3, Days 0/7/14, sacrifice Day 21)
“GLP Status No”
✓ VerifiedFDA pharmacology/toxicology review, p. 12Source ↗
Route in tox
Subcutaneous (clinical route)
“Route of Administration SC”
✓ VerifiedFDA pharmacology/toxicology review, p. 12Source ↗

Same question, other gene therapies

Adstiladrin

nadofaragene firadenovec · IFN-alpha2b (adenovirus, intravesical)
22 (derived from the dosing and observation schedule)

Beqvez

fidanacogene elaparvovec · Factor IX
104 weeks

Casgevy

exagamglogene autotemcel · BCL11A enhancer (CRISPR-Cas9, ex vivo HSC)
20 weeks

Elevidys

delandistrogene moxeparvovec · Micro-dystrophin
24 weeks

Fayuvi

rebisufligene etisparvovec · SGSH (AAV9)
26 weeks

Genglycos

pariglasgene brecaparvovec · G6PC (AAV8)
26 weeks

Glybera

alipogene tiparvovec · LPL (AAV1)
26 weeks

Hemgenix

etranacogene dezaparvovec · Factor IX
26 weeks

Imlygic

talimogene laherparepvec · GM-CSF (oncolytic HSV-1)
12 (derived from the dosing and observation schedule)

Itvisma

onasemnogene abeparvovec (intrathecal) · SMN1 (AAV9, intrathecal)
52 weeks

Kebilidi

eladocagene exuparvovec · AADC
26 weeks

Kresladi

marnetegragene autotemcel · ITGB2 (LVV, ex vivo HSC)
4 weeks

Lenmeldy

atidarsagene autotemcel · ARSA (LVV, ex vivo HSC)
52 weeks

Luxturna

voretigene neparvovec · RPE65
31 weeks

Lyfgenia

lovotibeglogene autotemcel · HBB T87Q (LVV, ex vivo HSC)
26 weeks

Otarmeni

lunsotogene parvec · OTOF (AAV, intracochlear)
27 weeks

Roctavian

valoctocogene roxaparvovec · Factor VIII
26 weeks

Skysona

elivaldogene autotemcel · ABCD1 (LVV, ex vivo HSC)
13 (derived from the dosing and observation schedule)

Strimvelis

autologous CD34+ cells transduced with ADA (no INN) · ADA (gamma-retroviral, ex vivo HSC)
16 weeks

Tudriqev

vusolimogene oderparepvec · GALV-GP + GM-CSF (oncolytic HSV-1)
26 weeks

Vyjuvek

beremagene geperpavec · COL7A1 (HSV-1, topical)
9 (derived from the dosing and observation schedule)

Waskyra

etuvetidigene autotemcel · WAS (LVV, ex vivo HSC)
64 weeks

Zevaskyn

prademagene zamikeracel · COL7A1 (RV-modified keratinocyte sheets)
8 weeks

Zolgensma

onasemnogene abeparvovec · SMN1
26 weeks

Zynteglo

betibeglogene autotemcel · HBB T87Q (LVV, ex vivo HSC)
26 weeks

Summary across all 26 gene therapies →